88

AimsHyperuricemia is associated with an increased risk of mortality in coronary heart disease (CHD) patients. Magnesium intake is related to reduced mortality due to cardiovascular disease. This study aimed to investigate the association between dietary magnesium intake, magnesium depletion score (MDS) and hyperuricemia-related all-cause mortality or cardiovascular mortality in patients with CHS.MethodsIn this retrospective cohort study, 1,823 CHD patients were selected from the National Health and Nutrition Examination Survey (NHANES). Dietary magnesium intake was determined based on 24-hour dietary recall interviews. MDS was assessed considering four factors: use of diuretics, use of proton pump inhibitors, estimated glomerular filtration rate, and alcohol consumption. Weighted univariate and multivariate Cox regression models were applied to explore the association between dietary magnesium intake, MDS, hyperuricemia, and all-cause mortality or cardiovascular mortality. The results were presented as hazard ratios (HRs) and 95% confidence intervals (CIs). The Kaplan-Meier survival curves were used to explore survival status relative to magnesium intake or MDS.ResultsAfter an average of 81 months of follow-up, 879 CHD patients died. After adjusting for covariates, MDS ≥2 (HR=1.34, 95% CI: 1.13-1.60) and hyperuricemia (HR=1.25, 95% CI: 1.01-1.55) were associated with increased odds of all-cause mortality. Moreover, MDS affected the association between hyperuricemia and all-cause mortality (HR=1.41, 95% CI: 1.09-1.84) or cardiovascular mortality (HR=1.44, 95% CI: 1.02-2.03) in CHD patients.ConclusionMDS influences mortality in patients with hyperuricemia, highlighting the potential importance of magnesium status in managing the risks associated with hyperuricemia in CHD patients.